Clinical Trials Browser

Phase 2 × Lymphoma, B-Cell, Marginal Zone × ME-401 × Clear all

NCT03768505 2024-12-31

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Phase 2 Terminated

169 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone